Literature DB >> 23467237

Metastasis awakening: the challenges of targeting minimal residual cancer.

Bernhard Polzer1, Christoph A Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23467237     DOI： 10.1038/nm.3121

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

1.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Authors:  Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

Authors:  Steven R Alberts; Daniel J Sargent; Suresh Nair; Michelle R Mahoney; Margaret Mooney; Stephen N Thibodeau; Thomas C Smyrk; Frank A Sinicrope; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Anthony F Shields; James T Quesenberry; Thomas A Webb; Gist H Farr; Barbara A Pockaj; Axel Grothey; Richard M Goldberg
Journal:  JAMA       Date:  2012-04-04       Impact factor: 56.272

4.  The life history of 21 breast cancers.

Authors:  Serena Nik-Zainal; Peter Van Loo; David C Wedge; Ludmil B Alexandrov; Christopher D Greenman; King Wai Lau; Keiran Raine; David Jones; John Marshall; Manasa Ramakrishna; Adam Shlien; Susanna L Cooke; Jonathan Hinton; Andrew Menzies; Lucy A Stebbings; Catherine Leroy; Mingming Jia; Richard Rance; Laura J Mudie; Stephen J Gamble; Philip J Stephens; Stuart McLaren; Patrick S Tarpey; Elli Papaemmanuil; Helen R Davies; Ignacio Varela; David J McBride; Graham R Bignell; Kenric Leung; Adam P Butler; Jon W Teague; Sancha Martin; Goran Jönsson; Odette Mariani; Sandrine Boyault; Penelope Miron; Aquila Fatima; Anita Langerød; Samuel A J R Aparicio; Andrew Tutt; Anieta M Sieuwerts; Åke Borg; Gilles Thomas; Anne Vincent Salomon; Andrea L Richardson; Anne-Lise Børresen-Dale; P Andrew Futreal; Michael R Stratton; Peter J Campbell
Journal:  Cell       Date:  2012-05-17       Impact factor: 41.582

5.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Authors:  Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbauer; Aron Goldhirsch; Michael Untch; Ian Smith; José Baselga; Christian Jackisch; David Cameron; Max Mano; José Luiz Pedrini; Andrea Veronesi; Cesar Mendiola; Anna Pluzanska; Vladimir Semiglazov; Eduard Vrdoljak; Michael J Eckart; Zhenzhou Shen; George Skiadopoulos; Marion Procter; Kathleen I Pritchard; Martine J Piccart-Gebhart; Richard Bell
Journal:  Lancet Oncol       Date:  2011-02-25       Impact factor: 41.316

6.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer.

Authors:  Julian A Schardt; Manfred Meyer; Claudia H Hartmann; Falk Schubert; Oleg Schmidt-Kittler; Christine Fuhrmann; Bernhard Polzer; Marco Petronio; Roland Eils; Christoph A Klein
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

7.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

8.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.

Authors:  C-H Gow; Y-L Chang; Y-C Hsu; M-F Tsai; C-T Wu; C-J Yu; C-H Yang; Y-C Lee; P-C Yang; J-Y Shih
Journal:  Ann Oncol       Date:  2008-12-16       Impact factor: 32.976

Review 9.  Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis.

Authors:  Nikolas H Stoecklein; Christoph A Klein
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

10.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245
View more
  28 in total

Review 1.  Tumor metastasis: moving new biological insights into the clinic.

Authors:  Liling Wan; Klaus Pantel; Yibin Kang
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 2.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

3.  Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness.

Authors:  Shuya Yano; Yong Zhang; Shinji Miwa; Yasunori Tome; Yukihiko Hiroshima; Fuminari Uehara; Mako Yamamoto; Atsushi Suetsugu; Hiroyuki Kishimoto; Hiroshi Tazawa; Ming Zhao; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2014-05-08       Impact factor: 4.534

4.  Selection and adaptation during metastatic cancer progression.

Authors:  Christoph A Klein
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

5.  Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.

Authors:  M Banys-Paluchowski; H Schneck; C Blassl; S Schultz; F Meier-Stiegen; D Niederacher; N Krawczyk; E Ruckhaeberle; T Fehm; H Neubauer
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-03       Impact factor: 2.915

Review 6.  KISS1 in metastatic cancer research and treatment: potential and paradoxes.

Authors:  Thuc Ly; Sitaram Harihar; Danny R Welch
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 7.  Premetastatic niche formation in the liver: emerging mechanisms and mouse models.

Authors:  Achim Krüger
Journal:  J Mol Med (Berl)       Date:  2015-09-24       Impact factor: 4.599

Review 8.  Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.

Authors:  Noa Biran; Scott Ely; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

9.  Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Authors:  Tim Kottke; Laura Evgin; Kevin G Shim; Diana Rommelfanger; Nicolas Boisgerault; Shane Zaidi; Rosa Maria Diaz; Jill Thompson; Elizabeth Ilett; Matt Coffey; Peter Selby; Hardev Pandha; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Cancer Immunol Res       Date:  2017-10-15       Impact factor: 11.151

10.  The importance of developing therapies targeting the biological spectrum of metastatic disease.

Authors:  Andries Zijlstra; Ariana Von Lersner; Dihua Yu; Lucia Borrello; Madeleine Oudin; Yibin Kang; Erik Sahai; Barbara Fingleton; Ulrike Stein; Thomas R Cox; John T Price; Yasumasa Kato; Alana L Welm; Julio A Aguirre-Ghiso
Journal:  Clin Exp Metastasis       Date:  2019-05-17       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.